索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]王晓菲,黄淑田.非酒精性脂肪性肝病与心血管疾病[J].国际心血管病杂志,2024,03:167-170.
点击复制

非酒精性脂肪性肝病与心血管疾病(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2024年03期
页码:
167-170
栏目:
综述
出版日期:
2024-05-20

文章信息/Info

Title:
-
作者:
王晓菲; 黄淑田
030001 太原，山西医科大学（王晓菲）；030001 山西 医科大学第二医院心内科（黄淑田）
Author(s):
-
关键词:
非酒精性脂肪性肝病; 心血管疾病; 代谢综合征
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2024.03.011
文献标识码:
-
摘要:
非酒精性脂肪性肝病（NAFLD）与代谢综合征密切相关。NAFLD 患者心血管 疾病的发病率显著增高，且NAFLD 是心血管疾病的独立危险因素。胰岛素抵抗、肠道菌群 失调和遗传因素共同参与二者的发病机制。目前尚无专门针对NAFLD 的治疗药物，某些心 血管药物显示出对NAFLD 患者有益。
Abstract:
-

参考文献/References

[1] European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASLEASD- EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease[J]. Diabetologia, 2016, 59(6):1121-1140.
[2] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement[J]. J Hepatol, 2020, 73(1):202-209.
[3] Chen Z, Yu Y, Cai J, et al. Emerging molecular targets for treatment of nonalcoholic fatty liver disease[J]. Trends Endocrinol Metab, 2019, 30(12):903-914.
[4] Hodson L, Gunn PJ. The regulation of hepatic fatty acid synthesis and partitioning: the effect of nutritional state[J]. Nat Rev Endocrinol, 2019, 15(12):689-700.
[5] Nassir F. NAFLD: mechanisms, treatments, and biomarkers[J]. Biomolecules, 2022, 12(6):824.
[6] Cai J, Zhang XJ, Ji YX, et al. Nonalcoholic fatty liver disease pandemic fuels the upsurge in cardiovascular diseases[J]. Circ Res, 2020, 126(5):679-704.
[7] 程方. 胰岛素抵抗与心血管病理生理机制分析[J]. 中西医结合 心血管病电子杂志, 2020, 8(9):16-17.
[8] Jeong MK, Min BH, Choi YR, et al. Food and gut microbiotaderived metabolites in nonalcoholic fatty liver disease[J]. Foods, 2022, 11(17):2703.
[9] Fang J, Yu CH, Li XJ, et al. Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications[J]. Front Cell Infect Microbiol, 2022, 12:997018.
[10] Cazac GD, L?c?tu?u CM, Mihai C, et al. New insights into nonalcoholic fatty liver disease and coronary artery disease: the liverheart axis[J]. Life (Basel), 2022, 12(8):1189.
[11] Simons N, Isaacs A, Koek GH, et al. PNPLA3, TM6SF2, and MBOAT7 genotypes and coronary artery disease[J]. Gastroenterology, 2017, 152(4):912-913.
[12] Wen W, Li H, Wang C, et al. Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: a meta-analysis[J]. Front Endocrinol (Lausanne), 2022, 13:934225.
[13] Yan LH, Mu B, Guan Y, et al. Assessment of the relationship between non-alcoholic fatty liver disease and diabetic complications[J]. J Diabetes Investig, 2016, 7(6):889-894.
[14] Targher G, Byrne CD, Lonardo A, et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a metaanalysis[ J]. J Hepatol, 2016, 65(3):589-600.
[15] Wu S, Wu F, Ding Y, et al. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis[J]. Sci Rep, 2016, 6:33386.
[16] Li H, Yu XH, Ou X, et al. Hepatic cholesterol transport and its role in non-alcoholic fatty liver disease and atherosclerosis[J]. Prog Lipid Res, 2021, 83:101109.
[17] Sinn DH, Cho SJ, Gu S, et al. Persistent nonalcoholic fatty liver disease increases risk for carotid atherosclerosis[J]. Gastroenterology, 2016, 151(3):481-488. e1.
[18] Bae YS, Ko YS, Yun JM, et al. Association and prediction of subclinical atherosclerosis by nonalcoholic fatty liver disease in asymptomatic patients[J]. Can J Gastroenterol Hepatol, 2020, 2020:8820445.
[19] Taylan G, Ebik M, Solak S, et al. Risk of premature coronary atherosclerosis in patients with nonalcoholic fatty liver disease[J]. Rev Assoc Med Bras (1992), 2022, 68(10):1428-1433.
[20] Cattazzo F, Lombardi R, Mantovani A, et al. Subclinical and clinical atherosclerosis in non-alcoholic fatty liver disease is associated with the presence of hypertension[J]. Nutr Metab Cardiovasc Dis, 2022, 32(12):2839-2847.
[21] Chen Z, Liu J, Zhou F, et al. Nonalcoholic fatty liver disease: an emerging driver of cardiac arrhythmia[J]. Circ Res, 2021, 128(11):1747-1765.
[22] Targher G, Valbusa F, Bonapace S, et al. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes[J]. PLoS One, 2013, 8(2):e57183.
[23] K?r?j?m?ki AJ, P?tsi OP, Savolainen M, et al. Non-alcoholic fatty liver disease as a predictor of atrial fibrillation in middleaged population (OPERA Study)[J]. PLoS One, 2015, 10(11):e0142937.
[24] Gong H, Liu X, Cheng F. Relationship between nonalcoholic fatty liver disease and cardiac arrhythmia: a systematic review and meta-analysis[J]. J Int Med Res, 2021, 49(9):3000605211047074.
[25] Long MT, Yin X, Larson MG, et al. Relations of liver fat with prevalent and incident atrial fibrillation in the Framingham Heart Study[J]. J Am Heart Assoc, 2017, 6(5):e005227.
[26] 周杭燚, 梁芬, 吕东岭. 心包脂肪组织与心血管疾病关系的研 究进展[J]. 临床医学研究与实践, 2022, 7(15):183-187.
[27] Mantovani A, Byrne CD, Benfari G, et al. Risk of heart failure in patients with nonalcoholic fatty liver disease: JACC review topic of the week[J]. J Am Coll Cardiol, 2022, 79(2):180-191.
[28] Anstee QM, Mantovani A, Tilg H, et al. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(7):425-439.
[29] Fan N, Ding X, Zhen Q, et al. Association of the Non-Alcoholic Fatty Liver Disease Fibrosis Score with subclinical myocardial remodeling in patients with type 2 diabetes: a cross-sectional study in China[J]. J Diabetes Investig, 2021, 12(6):1035-1041.
[30] Van Wagner LB, Wilcox JE, Ning H, et al. Longitudinal association of non-alcoholic fatty liver disease with changes in myocardial structure and function: the CARDIA study[J]. J Am Heart Assoc, 2020, 9(4):e014279.
[31] Canada JM, Abbate A, Collen R, et al. Relation of hepatic fibrosis in nonalcoholic fatty liver disease to left ventricular diastolic function and exercise tolerance[J]. Am J Cardiol, 2019, 123(3):466-473.
[32] Boutari C, Pappas PD, Anastasilakis D, et al. Statins' efficacy in non-alcoholic fatty liver disease: a systematic review and metaanalysis[ J]. Clin Nutr, 2022, 41(10):2195-2206.
[33] Zou B, Odden MC, Nguyen MH. Statin use and reduced hepatocellular carcinoma risk in patients wth nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2023, 21(2):435- 444. e6.
[34] Kreiner FF, Hovingh GKK, von Scholten BJ. The potential of glucagon-like peptide-1 receptor agonists in heart failure[J]. Front Physiol, 2022, 13:983961.
[35] Ferrari F, Scheffel RS, Martins VM, et al. Glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus and cardiovascular disease: the past, present, and future[J]. Am J Cardiovasc Drugs, 2022, 22(4):363-383.
[36] Ying X, Rongjiong Z, Kahaer M, et al. Therapeutic efficacy of liraglutide versus metformin in modulating the gut microbiota for treating type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease[J]. Front Microbiol, 2023, 14:1088187.
[37] Bellanti F, Lo Buglio A, Dobrakowski M, et al. Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/ inflammation and redox balance in non-alcoholic fatty liver disease[J]. World J Gastroenterol, 2022, 28(26):3243-3257.
[38] Elrashidy RA, Asker ME, Mohamed HE. Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy[J]. J Cardiovasc Pharmacol Ther, 2012, 17(3):324- 333.
[39] Polyzos SA, Kechagias S, Tsochatzis EA. Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations[J]. Aliment Pharmacol Ther, 2021, 54(8):1013-1025.
[40] 李云, 刘天宇, 张文军. 肝肠法尼酯X受体在代谢性疾病中的作 用研究进展[J]. 天津药学, 2023, 35(1):71-78.
[41] Rinella ME, Tacke F, Sanyal AJ, et al. Report on the AASLD/ EASL joint workshop on clinical trial endpoints in NAFLD[J]. J Hepatol, 2019, 71(4):823-833.

备注/Memo

备注/Memo:
通信作者：黄淑田， E-mail：huangshutian9@126.com
更新日期/Last Update: 2024-05-20